No Data
China Post Securities: The old-for-new policy has entered the implementation phase, and the medical devices sector is expected to enter a period of high performance growth.
It is expected that in December and the first quarter of 2025, various provinces will gradually implement the trade-in policy, relevant hospital tenders will be initiated, and equipment manufacturers are expected to see a large number of trade-in orders in the fourth quarter.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) Price Is Right But Growth Is Lacking
AVIC Securities: The pharmaceutical industry's performance in the third quarter is under pressure, with the total market value of heavyweight holdings by funds increasing.
The demand for blood sector in the biological products sector remains strong, with vaccine sales under pressure due to factors such as previous market consumption; the active pharmaceutical ingredient sector is entering the final stage of downstream inventory, showing an improvement in demand, and future performance is expected to gradually improve.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Stock Goes Ex-Dividend In Just Two Days
Shenzhen Mindray Bio-Medical Electronics (300760.SZ): Continuous strengthening of business matrix through mergers and acquisitions, achieving industry-leading growth.
Against the backdrop of the continuous growth in global demand for medical instruments, an undeniable phenomenon is that medical instrument companies, especially leading ones, are utilizing external expansion mergers to quickly seize market opportunities and further enhance performance. Drawing from the growth path of global medical instrument giants that span hundreds of years, it can be seen that mergers and acquisitions are a necessary path for enterprises to achieve rapid growth and industry leadership. According to incomplete statistics from public data, as of 2024, foreign-funded medical instrument companies have completed 12 mergers and acquisitions, with a total amount reaching approximately 168.59 billion Chinese yuan, covering cardiovascular intervention, stroke pre
Earnings Miss: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Missed EPS By 13% And Analysts Are Revising Their Forecasts
No Data
No Data
102884128 : getting disappointed with this counter. every day drop.